Foxiling (butaselen) / Shanghai Yuanxi Pharma - LARVOL DELTA

Butaselen combined with radiotherapy for newly diagnosed H3K27M-mutant spinal diffuse midline glioma: A single-arm phase Ib trial. (ASCO 2026) - P1/2 | "Butaselen combined with standard radiotherapy was well tolerated, and exhibited meaningful prolongation of survival period, durable objective responses and neurological function improvements in primary H3K27M-mutant sDMG patients."

P1 data • Brain Cancer • Diffuse Midline Glioma • Glioma • Orthopedics • Solid Tumor

Phase I, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, and Pharmacokinetics of BS1801 in Healthy Chinese Adult Subjects. (PubMed, Drug Des Devel Ther) - "Based on safety and PK profiles, the recommended dosage is 300-450 mg twice daily. Further clinical studies are needed for evaluating the safety and efficacy of BS1801 in the target population."

Clinical • Journal • PK/PD data • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology

A multiple-center, randomized, double-blind, placebo-controlled phase IIb clinical trial evaluating the safety and efficacy of standard treatment in combination with butaselen tablets in patients with fibrosing interstitial lung disease (ChiCTR) - P2 | N=48 | Recruiting | Sponsor: China-Japan Friendship Hospital; Shanghai Yuanxi Medicine Corp.

New P2 trial • Fibrosis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

The combined inhibitory effect of butaselen and decitabine against lung cancer cells. (PubMed, Sci Rep) - "The combined treatment was associated with downregulation of DNMT1, a reduced Bcl‑2/Bax ratio, and upregulation of HOXA9, p21, and E‑cadherin. These preclinical findings suggest that the combination of BS and DAC represents a mechanistically rationalized and promising therapeutic strategy for lung cancer that warrants further evaluation in in vivo models and early‑phase clinical trials."

Journal • Hematological Disorders • Hematological Malignancies • Lung Cancer • Oncology • Solid Tumor • ANXA5 • BAX • BCL2 • CDH1 • CDKN1A • DNMT1 • HOXA9

A single-center, open-label, single-arm clinical phase Ib/IIa trial of butaselen combined with radiotherapy for primary postoperative high-grade spinal cord gliomas (ChiCTR) - P1/2 | N=15 | Recruiting | Sponsor: Beijing Tiantan Hospital, Capital Medical University; Shanghai Yuanxi Medical Technology Co., LTD

New P1/2 trial • Brain Cancer • Glioma • Oncology • Solid Tumor

Evaluation of the quality, accuracy, and reliability of YouTube™ videos on laminate veneer treatment in Turkish. (PubMed, BMC Oral Health) - "In this study in which YouTubeTM videos about laminate veneer treatment were analysed, it was discovered that the accuracy and reliability level of the videos are moderate. Patients wishing to acquire information regarding the treatment are indeed able to do so reliably by watching these videos. Moreover, the number of quality videos for educational purposes should be increased for dental students."

Journal

The novel thioredoxin reductase inhibitor butaselen suppresses lung cancer by inducing oxidative stress. (PubMed, Redox Rep) - "The TrxR/Trx inhibitor butaselen suppresses lung cancer by triggering ROS-induced apoptosis. This study provides a novel and effective regimen for treating lung cancer."

Journal • Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • CDKN1A • DNMT1 • HBP1 • HOXA9

Novel Thioredoxin reductase 1 inhibitor BS1801 relieves treatment resistance and triggers endoplasmic reticulum stress by elevating reactive oxygen species in glioma. (PubMed, Redox Biol) - "Glioma patients will inevitably develop resistance to temozolomide (TMZ) leading to tumor recurrence. In summary, BS1801 treatment can elevate ROS levels, induce glioblastoma cell apoptosis and activate ER stress, thereby relieving TMZ resistance. BS1801 exhibits potent glioma inhibitory effects and potential clinical application."

Journal • Brain Cancer • Glioblastoma • Glioma • Metabolic Disorders • Oncology • Solid Tumor

Orphan Designation: treatment of cholangiocarcinoma (FDA) - Date Designated: 12/05/2024

Orphan drug • Cholangiocarcinoma